Anti-Inflammatory Therapy for Cerebral Small Vessel Disease: Genetic Evidence for Potential Druggable Targets
In this #BloggingStroke post, @B_Rioux discusses #Stroke article by Sun et al. #AHAJournals
https://t.co/snKEmgEVzT
In this Blogging stroke, I discuss MRI "predictors" of cognitive function after stroke and explain why they are difficult to interpret clinically.
"Risk estimations in the clinic — including intuitions or ‘gestalt’ — are inherently multivariable."
https://t.co/yeb8OBeAYh
Can Proteomic Profiling Help Predict Incident Ischemic Stroke in the General Population?
In this #BloggingStroke post, @B_Rioux discusses #Stroke article by Gan et al. #AHAJournals
https://t.co/sKk2yj8YyO
Research by @HuntLabEdin & @DrMcglasson (UK DRI at Edinburgh) sheds light on the mechanisms behind RVCL-S, a rare genetic disorder that affects small blood vessels.
The study identifies an important therapeutic target👉 https://t.co/GjSimnoLrq
Our work led by Sarah McGlasson and colleagues from the Hunt lab at UK DRI Edinburgh sheds light on a rare genetic disease caused by DNA damage in small blood vessels
Powerful translational approach using UK Biobank and mechanistic studies on TREX1
https://t.co/1uMAKHaJUB
Can Serum Biomarkers Help Detect Hemorrhagic Transformation After Intravenous Thrombolysis in Acute Ischemic Stroke?
In this #BloggingStroke post, @B_Rioux discusses #Stroke article by Guo et al. @NguyenThanhMD#AHAJournals
https://t.co/eyZ7Hu7hsa
Can Age-Stratified Genetic Analyses Help Identify Risk Factors for Stroke in Younger Adults?
In this #BloggingStroke post, @B_Rioux discusses #Stroke article by Nguyen et al. #AHAJournals
https://t.co/5cpU99vmxG
Nouvelle/new publication!👇
https://t.co/1fyTnxom4D
DIDO times in Québec and clinical outcomes among EVT-treated pts.
🧠 Great work from Dr Joel Neves Briard, Aymen Sahal, colleagues from all EVT sites in QC and @INESSS_Qc@INR_CHUM
Early Direct Oral Anticoagulant Initiation is Generally Safe in Ischemic Stroke Associated With Atrial Fibrillation
In this #BloggingStroke post, @B_Rioux discusses @TheLancet article by Werring et al. on the OPTIMAS trial. @BoNorrving
https://t.co/SxUtF0zjEB
Did you know 300 million people live with a rare disease worldwide?
This #RareDiseaseDay, we're spotlighting @HuntLabEdin (UK DRI at Edinburgh). The lab is researching a gene called TREX1, which when faulty, causes 2 different rare brain diseases 🧬 🧠
🎥 @DrMcglasson explains ⬇️
2/2 New mechanistic discoveries will be facilitated through a shift towards biologically-derived phenotypes, age-stratified analyses and inclusion of diverse ancestry populations.
1/2 Excellent review by John Hardy (UK DRI at UCL) on the genetic architectures of neurodegenerative diseases and how our current understand of failing damage clearance systems can inform future GWASs.
https://t.co/3kPm65KMGd